Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Anu Osinusi, Roberto Mateo, Wan‐Long Chuang, Henry Lik‐Yuen Chan et al.
Citations
19 citations
Journal
Alimentary Pharmacology & Therapeutics
Topics
Hepatitis B Virus Studies
Field-Weighted Citation Impact (FWCI)
7.35
article
Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Anu Osinusi, Roberto Mateo, Wan‐Long Chuang, Henry Lik‐Yuen Chan, Maciej Jabłkowski, Leland J. Yee, Harry L.A. Janssen, John F. Flaherty, Marı́a Buti, Scott Fung, Kosh Agarwal, Calvin Q. Pan, Dzhamal Abdurakhmanov, Maurizia Rossana Brunetto, Irina Botros, Young‐Suk Lim, Edward Gane, Hongyuan Wang, X. Shalimar, Patrick Marcellin, Wai‐Kay Seto, Frida Abramov, Namiki Izumi
University of Pisa (IT), Ulsan College (KR), University of Auckland (NZ), Inserm (FR), Chinese University of Hong Kong (HK), Sechenov University (RU), University of Toronto (CA), Hôpital Beaujon (FR), Instituto de Salud Carlos III (ES), Asan Medical Center (KR), Erasmus MC (NL), Kaohsiung Medical University Chung-Ho Memorial Hospital (TW), University of Ulsan (KR), Assistance Publique – Hôpitaux de Paris (FR), King's College Hospital NHS Foundation Trust (GB), Medical University of Lodz (PL), Vall d'Hebron Hospital Universitari (ES), Gilead Sciences (United States) (US), Musashino Red Cross Hospital (JP), New York University (US), All India Institute of Medical Sciences (IN), University of Hong Kong (HK)